As the LUX-Lung 8 trial underline benefit from the anti-EGFR tyrosine kinase inhibitor among lung squamous patients associated with ERBB alterations, the occurrence of 5.8% EGFR mutations among Indian lung squamous cell carcinoma patients emphasizes the potential significance and relevance of the outcome of this trial in the Indian context [35]. This evidence concerns the gene EGFR and squamous cell lung carcinoma.